Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Left Ventricular Wall Thickness
研究概览
简要总结
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.
详细描述
Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at Mayo Clinic will be eligible.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically and echocardiographically defined hypertrophic cardiomyopathy.
- •Clinically indicated transthoracic echocardiography as part of the medical evaluation.
- •No contradiction to administration of ultrasonic echocardiography contrast.
- •Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
- •No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
- •Age 18 years and older
排除标准
- •Insufficient image quality for determination of maximal wall thickness.
结局指标
主要结局
Left Ventricular Wall Thickness
时间窗: approximately 1 week after enrollment
All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
次要结局
未报告次要终点
研究者
Patricia A. Pellikka
Professor of Medicine, College of Medicine
Mayo Clinic